Compare Indonesia Energy Corporation Limited (INDO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Merck & Co., Inc. — how do they compare? Indonesia Energy Corporation Limited trades at $2.85 (market cap $43.24M), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8124× Indonesia Energy Corporation Limited's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Merck & Co., Inc. for 98 Days on average.
| INDO | MRK | |
|---|---|---|
Market Cap | $43.24M | $351.28B |
Volume | 116,953 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $6.74 | $156.43 |
52-Week Low | $2.49 | $82.49 |
Typical Hold Time | 24 Days | 98 Days |
Enterprise Value | $38.18M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77, unchanged on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $5.10 million in 2025 on revenue of $2.01 million, reflecting negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with negative profitability and cash burn. Investment potential hinges on successful execution of drilling operations to boost revenue, but risks include sustained losses, high valuation multiples relative to sales, and reliance on financing activities.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
